Prostamax — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Prostamax

Also known as: Lys-Glu-Asp-Pro, KEDP, peptide bioregulator prostamax

Synthetic short-chain oligopeptide bioregulator / epigenetic regulator

Research chemicalLast updated: October 19, 2026Based on 6 peer-reviewed studies

What it is

Prostamax is a short peptide studied for prostate health and anti-aging effects, with research suggesting it influences gene activity in aging prostate and immune cells. It is investigated as part of a class of epigenetically active bioregulatory peptides. No FDA-approved use; primarily studied in Russian research with limited independent replication.

The scientific side

Prostamax (Lys-Glu-Asp-Pro) is a short synthetic oligopeptide bioregulator studied primarily for its effects on chromatin structure in aging cells. Published studies report that it promotes decondensation of heterochromatin and deheterochromatinization of facultative chromatin in human lymphocytes from elderly subjects, leading to activation of ribosome genes and release of genes repressed by age-related chromatin condensation. Biophysical studies using differential scanning calorimetry indicate it causes redistribution of thermal energy among chromatin denaturation endotherms and shifts denaturation temperatures to lower values, interpreted as partial relaxation of the 30-nm chromatin fiber. In organotypic tissue culture (rat), a concentration of 0.05 ng/ml showed a stimulating effect on prostate explants compared to controls.

Class: Synthetic short-chain oligopeptide bioregulator / epigenetic regulator

Administration & storage

Administration
In vitro cell culture application (PMID: 15085253232211441561255119359734)In vitro organotypic tissue culture application (PMID: 17152728)
Storage
No storage conditions for Prostamax are described in the reviewed abstracts.
Cautions
All published studies identified in this review are in vitro or ex vivo cell/tissue culture experiments; no human pharmacokinetic, pharmacodynamic, or safety data are available from these abstracts.,No clinical trials, in vivo human dosing studies, or formal toxicology data were identified in the reviewed literature.,Sterile technique is essential for any peptide handling to prevent contamination.,The purity and source of Prostamax used in any preparation should be verified, as research-grade and commercial preparations may differ substantially in quality.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification